Edotreotide Powder Cas No.204318-14-9
English alias: DOTATOC
Product source: artificially synthesized
Product specifications: ≥ 98%
CAS NO：204318 - 14 - 9
Detection method: HPLC
Active ingredient: Edotriotide
Product Description: White to off white freeze-dried powder
Product packaging: It is packaged in penicillin bottles with good sealing properties, and the packaging specifications are determined according to the product specifications
Product storage: Store at a low temperature of -20 ℃, away from light.
Avoid repeated freezing and thawing.
Shelf life: 24-36 months
Edotreotide API Powder CAS 204318-14-9 | Radiopharmaceutical Precursor Peptide
Edotreotide (CAS 204318-14-9) supplied by Xi'an Tihealth is a high-purity somatostatin analog peptide explicitly synthesized as a precursor for the development of radiopharmaceuticals. Through advanced solid-phase synthesis and rigorous multi-stage HPLC-UV purification, we deliver exceptional structural fidelity designed for targeted diagnosis and therapy of neuroendocrine tumors (NETs).
Our Edotreotide API is optimized for somatostatin receptor (SSTR2 and SSTR5) affinity and is strictly monitored for endotoxin levels to meet the stringent sterile requirements essential for radionuclide labeling. *Note: This raw material is provided strictly for industrial formulation, nuclear medicine R&D, and is not a finished pharmaceutical product.
Key Technical Advantages for Radiopharmaceutical R&D
- Ultra-Low Endotoxin Levels: Strictly controlled to < 10 EU/mg, meeting critical sterile requirements for successful nuclear drug labeling and formulation.
- Exceptional Purity Profile: Validated by HPLC-UV/ELSD dual screening to guarantee overall purity > 98.0% and single impurity limits strictly < 0.1%.
- Batch-to-Batch Consistency: Inter-batch variance of key indicators is maintained at < 2%, ensuring highly reproducible radiolabeling yields for clinical translation.
- Targeted Mechanism: Acts as a highly specific SSTR2/SSTR5 agonist, enabling precise in vivo imaging (e.g., SPECT/PET) and targeted radionuclide therapy for secretory neuroendocrine cells.
Technical Data Sheet (TDS)
| Technical Parameter | Specification / Limit |
|---|---|
| Product Name | Edotreotide (DOTATOC precursor) |
| CAS Number | 204318-14-9 |
| Purity (HPLC-UV) | > 98.0% |
| Single Impurity | < 0.1% |
| Endotoxin Level | < 10 EU/mg |
| Application | Radiolabeling precursor for NET diagnosis and therapy R&D |
Frequently Asked Questions
Is this peptide ready for direct clinical injection?
No. This is a high-purity API precursor powder designed specifically for radiopharmaceutical manufacturers and nuclear medicine laboratories to perform radiolabeling procedures. It is strictly a raw material and not a finished, sterile injectable product.
Can we request documentation for the endotoxin testing?
Absolutely. Batch-specific Certificates of Analysis (COA) detailing the HPLC-UV purity (> 98.0%), single impurity limits (< 0.1%), and the LAL endotoxin test results (< 10 EU/mg) are provided to support your rigorous regulatory and formulation requirements.
What is the standard packaging and shipping protocol for this API?
Edotreotide API is lyophilized and packaged under strict inert and moisture-free conditions. We utilize rigorous cold-chain logistics protocols to maintain structural stability, minimize degradation, and preserve endotoxin limits during global transit.
Hot Tags: edotreotide powder cas no.204318-14-9, China edotreotide powder cas no.204318-14-9 manufacturers, suppliers, factory, tranexamic powder
You Might Also Like
Send Inquiry